These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29410009)

  • 21. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.
    Atmaca M; Tezcan E; Ustundag B
    J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.
    Huang TL; Chen JF
    Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
    Jena M; Mishra A; Mishra BR; Nath S; Maiti R
    Psychopharmacology (Berl); 2020 Nov; 237(11):3471-3480. PubMed ID: 32740676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.
    de Witte L; Tomasik J; Schwarz E; Guest PC; Rahmoune H; Kahn RS; Bahn S
    Schizophr Res; 2014 Apr; 154(1-3):23-9. PubMed ID: 24582037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.
    Tajiri M; Suzuki Y; Sugai T; Tsuneyama N; Someya T
    PLoS One; 2018; 13(7):e0199922. PubMed ID: 30016331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine.
    Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E
    Nord J Psychiatry; 2017 Feb; 71(2):89-95. PubMed ID: 27658459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
    Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latent Toxoplasma gondii infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia.
    Sagud M; Vlatkovic S; Svob Strac D; Sviben M; Zivkovic M; Vilibic M; Vuksan-Cusa B; Mihaljevic-Peles A; Pivac N
    Compr Psychiatry; 2018 Apr; 82():115-120. PubMed ID: 29477703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders.
    Gjerde PB; Jørgensen KN; Steen NE; Melle I; Andreassen OA; Steen VM; Agartz I
    Psychiatry Res Neuroimaging; 2018 Dec; 282():55-63. PubMed ID: 30415175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?
    Meier CA; Bobbioni E; Gabay C; Assimacopoulos-Jeannet F; Golay A; Dayer JM
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1184-8. PubMed ID: 11889184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased food intake and energy expenditure following administration of olanzapine to healthy men.
    Fountaine RJ; Taylor AE; Mancuso JP; Greenway FL; Byerley LO; Smith SR; Most MM; Fryburg DA
    Obesity (Silver Spring); 2010 Aug; 18(8):1646-51. PubMed ID: 20134408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration.
    Akiyama K
    Schizophr Res; 1999 May; 37(1):97-106. PubMed ID: 10227112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia.
    Fang X; Chen L; Wang D; Yu L; Wang Y; Chen Y; Ren J; Tang W; Zhang C
    Psychiatry Res; 2019 Nov; 281():112522. PubMed ID: 31521045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol.
    Raposo NR; Ferreira AS; Gattaz WF
    Pharmacopsychiatry; 2011 Jul; 44(5):169-72. PubMed ID: 21732272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.
    Bilgic S; Tastemir Korkmaz D; Azirak S; Guvenc AN; Kocaman N; Ozer MK
    Bratisl Lek Listy; 2017; 118(10):618-625. PubMed ID: 29198130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.